argenx SE reported $8.07B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AstraZeneca USD 27.97B 1.65B Jun/2026
Genmab DKK 2.88B 1.59B Dec/2025
GlaxoSmithKline GBP 17.56B 202M Jun/2026
GRIFOLS EUR 5.31B 51M Jun/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Lakefront Biotherapeutics EUR 3.06B 18.72M Mar/2026
Qiagen NV USD 1.54B 454.82M Mar/2026
UCB EUR 6.05B 733M Dec/2025